

Paris & New York, April 26th, 2016

Regulatory authorisations received in France to begin Phase IIa multicentric European trial for heart failure

Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces it has obtained authorisations from ANSM (the French national drug and health products safety agency) and CPP (the French consumer protection agency) to begin the Phase IIa trial for the treatment of heart failure (QGC101 program).

Dubbed *Quid HF (Heart Failure)*, this Phase IIa multicentric clinical trial on patients suffering from heart failure will be conducted in a number of European countries, including France. These regulatory authorisations for France will allow actual trials in the country's leading medical centers to be launched by mid-2016, more than six months ahead of the initial schedule. Quantum Genomics is also beginning to receive regulatory authorisations for other European countries.

Faiez Zannad, Professor of Therapeutic Cardiology at the University of Lorraine (Nancy CHU teaching hospital), will coordinate the *Quid HF* trial, in collaboration with Doctor Olivier Madonna, Chief Medical Officer at Quantum Genomics. Professor Zannad has previously conducted major international clinical trials for heart failure.

Quantum Genomics also confirms that the Phase IIa clinical trials for high blood pressure (QGC001 program) were completed in April 2016, as planned. The results will be released in the third quarter of 2016.

More than 23 million people worldwide suffer from heart failure

Heart failure is a major public health problem with a persistent urgent need for new therapeutic treatments. Despite some medical advances, the vital prognosis associated with heart failure is very poor as more than 50% of people diagnosed with heart failure die within five years.

Heart failure today affects some 5.8 million people in the United States alone and more than 23 million worldwide, according to American Heart Association data. Direct and indirect annual costs connected with heart failure worldwide in 2012 were an evaluated 108 billion dollars. The global market for heart failure drugs was estimated at 39 billion dollars in 2015.

CONTACTS

Quantum Genomics

Lionel Ségard
Chairman & Chief Executive Officer
+33 1 85 34 77 77

Quantum Genomics

Marc Karako
CFO – Investor Relations
+33 1 85 34 77 75
marc.karako@quantum-genomics.com

ACTUS finance et communication (Europe)

Jean-Michel Marmillon
Press Relations
+33 1 53 67 36 73
jmmarmillon@actus.fr

The Ruth Group (U.S.)

Lee Roth / Kirsten Thomas
Investor / Public Relations
+1 646-536-7012 / +1 508-280-6592

ABOUT QUANTUM GENOMICS

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.

Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.

Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).

The Company has offices in Paris, France and New York, NY, USA. For more information, please visit www.quantum-genomics.com.

 @ALQGC_EN

 Quantum Genomics